Outlook and Targets

Please read our caution about Forward-Looking Statements in the Conditions of Use when using this information.

Economic Outlook and Market Opportunities

Sales and Earnings Forecast

(published on April 30, 2015 in the Financial Report as of March 31, 2015)

Bayer Group

Based on the operational performance in the first quarter of 2015 and our expectations for the future business development, and taking into account the potential risks and opportunities, we are raising our guidance for 2015, mainly in view of the considerably more positive exchange rates prevailing on March 31, 2015.

We are now planning sales in the region of €48 billion to €49 billion (previously: in the region of €46 billion). This corresponds to a low-single-digit percentage increase on a currency- and portfolio-adjusted basis. We expect currency effects to boost sales by approximately 9% (previously: approximately 3%) compared with the prior year. We now plan to raise EBITDA before special items by a high-teens percentage (previously: low- to mid-teens percentage), allowing for expected positive currency effects of about 8% (previously: about 2%). We now aim to increase core earnings per share (calculated as explained in Chapter 7 of the Financial Report as of March 31, 2015) by a high-teens percentage (previously: low-teens percentage), allowing for expected positive currency effects of around 7% (previously: around 3%).

We continue to expect to take special charges in the region of €700 million, with the integration of the acquired consumer care businesses and the planned stock market listing of MaterialScience accounting for most of this amount.

We continue to anticipate the financial result to come in at around minus €1 billion and the effective tax rate at around 25% in 2015. We expect net financial debt at year end to be below €20 billion (previously: below €18 billion).

Further details of the business forecast are given in Chapter 20.2 of the Annual Report 2014.

HealthCare

At HealthCare we now expect sales to rise to over €24 billion (previously: approximately €23 billion). This corresponds to a mid-single-digit percentage increase on a currency- and portfolio-adjusted basis. We predict positive currency effects of about 9% (previously: about 3%) compared with 2014. We now plan to raise EBITDA before special items by a low-twenties percentage (previously: mid-teens percentage).

In the Pharmaceuticals segment, we now expect sales to move ahead to approximately €14 billion (previously: approximately €13 billion). This corresponds to a mid- to high-single-digit percentage on a currency- and portfolio-adjusted basis. Here we anticipate positive currency effects of about 9% (previously: about 2%) compared with 2014. We intend to raise sales of our recently launched products to over €4 billion (previously: toward €4 billion). We plan to raise EBITDA before special items by a mid-teens percentage (previously: low-teens percentage), allowing for an additional €350 million (previously: €300 million) of investment in research and development. As a result of the dilutive currency effects, we expect the EBITDA margin before special items to be slightly below the prior-year level (previously: slightly improve).

In the Consumer Health segment, we expect sales to increase to over €10 billion (previously: toward €10 billion), including those of the acquired consumer care businesses. We plan to grow sales by a mid-single-digit percentage on a currency- and portfolio-adjusted basis and anticipate positive currency effects of around 9% (previously: around 3%) compared with 2014. We expect to raise EBITDA before special items by a mid-thirties percentage (previously: a mid- to high-twenties percentage), with the acquired consumer care businesses contributing to the increase.

CropScience

At CropScience we expect to continue growing faster than the market and now aim to raise sales to approximately €11 billion (previously: approximately €10 billion). This corresponds to a low- to mid-single-digit percentage increase on a currency- and portfolio-adjusted basis. We anticipate positive currency effects of about 11% (previously: about 4%) compared with 2014. In line with the clearly positive currency changes, we now plan to improve EBITDA before special items by a low- to mid-teens percentage (previously: a low- to mid-single-digit percentage).

MaterialScience

At MaterialScience we continue to plan further volume growth in 2015 accompanied by declining selling prices. This will lead to lower sales on a currency- and portfolio-adjusted basis. However, we expect to see a significant increase in EBITDA before special items, partly due to lower raw material costs. We aim to return to earning the full cost of capital in 2015.

We expect sales and EBITDA before special items in the second quarter of 2015 to come in at least at the level of the first quarter of 2015.

Reconciliation

For 2015 we continue to anticipate sales on a currency- and portfolio-adjusted basis to be level with the previous year. We expect EBITDA before special items to be roughly minus €0.3 billion.

 

Sales and Earnings Forecast

(published on February 26, 2015 in the Annual Report 2014)

The following forecast is based on the business development described in the Annual Report 2014, taking into account the potential risks and opportunities and assuming the inclusion of the MaterialScience business for the full year.

Bayer Group

Our forecast for fiscal 2015 is based on the exchange rates as of December 31, 2014, including a rate of US$1.21 to the euro. A 1% appreciation (depreciation) of the euro against all other currencies would decrease (increase) sales on an annual basis by some €300 million and EBITDA before special items by about €70 million.

We are planning sales in the region of €46 billion for 2015. This corresponds to a currency- and portfolio-adjusted increase in the low single digits. We expect currency effects to boost sales by approximately 3% compared with the prior year. We plan to raise EBITDA before special items by a low- to mid-teens percentage, allowing for expected positive currency effects of about 2%. We aim to increase core earnings per share (calculated as explained in the Annual Report 2014, Chapter 16.3 “Core Earnings Per Share”) by a low-teens percentage, allowing for expected positive currency effects of around 3%.

We expect to take special charges in the region of €700 million in 2015, with the integration of the acquired consumer care businesses and the planned stock market listing of MaterialScience accounting for most of this amount.

 

We intend to increase our research and development spending by about 10% in 2015 to more than €4.0 billion. We have budgeted capital expenditures of about €2.3 billion for property, plant and equipment and €0.3 billion for intangible assets. Depreciation and amortization are estimated at about €3.0 billion, including €1.6 billion in amortization of intangible assets.

We predict the financial result to come in at around minus €1.0 billion. The effective tax rate is likely to be around 25%. We expect net financial debt to be below €18 billion at the end of 2015.

HealthCare

At HealthCare we expect sales to post a mid-single-digit percentage increase on a currency- and portfolio-adjusted basis to approximately €23 billion. We predict positive currency effects of about 3% compared with 2014. We plan to raise EBITDA before special items by a mid-teens percentage.

In the Pharmaceuticals segment, we expect sales to move ahead by a mid- to high-single-digit percentage on a currency- and portfolio-adjusted basis to approximately €13 billion. Here we anticipate positive currency effects of about 2% compared with 2014. We intend to raise sales of our recently launched products in 2015 toward €4 billion. We plan to raise EBITDA before special items by a low-teens percentage, allowing for an additional €300 million of investment in research and development. We therefore expect to slightly improve the EBITDA margin before special items.

In the Consumer Health segment, we expect sales to increase toward €10 billion, including those of the acquired consumer care businesses. We plan to grow sales by a mid-single-digit percentage on a currency- and portfolio-adjusted basis. Here we anticipate positive currency effects of around 3% compared with 2014. We expect to raise EBITDA before special items by a mid-to-high-twenties percentage, with the acquired consumer care businesses contributing to the increase.

CropScience

At CropScience we expect to continue growing faster than the market and to raise sales by a low- to mid-single-digit percentage on a currency- and portfolio-adjusted basis to approximately €10 billion. We anticipate positive currency effects of about 4% compared with 2014. We plan to improve EBITDA before special items by a low- to mid-single-digit percentage.

MaterialScience

At MaterialScience we are planning further volume growth in 2015 accompanied by declining selling prices, leading to lower sales. However, we expect to see a significant increase in EBITDA before special items. We aim to return to earning the full cost of capital in 2015.

Reconciliation

In 2015 we expect sales on a currency- and portfolio-adjusted basis to be level with the previous year. We are planning EBITDA before special items of approximately minus €0.3 billion.

Bayer AG

As the holding company for the Bayer Group, Bayer AG derives most of its income from its subsidiaries. The earnings of the major subsidiaries in Germany are transferred directly to Bayer AG under profit and loss transfer agreements. The earnings of Bayer AG are therefore expected to reflect the positive business development anticipated in the Bayer Group. A concerted dividend policy within the Group ensures the availability of sufficient distributable income. We expect an increase in net interest expense due to the higher level of net debt. Based on these factors, we expect Bayer AG to report a distributable profit that will again enable our stockholders to adequately participate in the Bayer Group’s earnings. 

Last updated: April 30, 2015 Copyright © Bayer AG